19 results about "Host disease" patented technology

This invention provides an antibody composition with improved stability, exhibiting reduced fragmentation of the antibody polypeptide chain during manufacturing and subsequent storage. [Solution] This disclosure relates to improved compositions and methods for treating T cell-mediated diseases and disorders (e.g., autoimmune disorders, graft-versus-host diseases, and graft rejection). Provided are antibody-containing anti-αβTCR binding polypeptides comprising at least one amino acid substitution or modification that enhances the stability of the binding polypeptide by reducing fragmentation of the light chain variable region. Methods provided herein generally involve administering an effective amount of a stabilized, humanized binding polypeptide specific to the alpha-beta T cell receptor (αβTCR) to a subject in need thereof.

The application discloses a method for establishing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, and belongs to the technical field of animal experiment model construction. The technical problem to be solved by the application is how to construct a mouse model which can be used to study the immune reconstruction mechanism and treatment effect evaluation of MHC haplotype compatibility and MHC full compatibility in bone marrow cell transplantation recipient mice. To solve the technical problem, the application provides a method for constructing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, which comprises transplanting bone marrow cells of a donor mouse into a recipient mouse, and the MHC haplotype of the donor mouse and the recipient mouse is compatible. The application sets a modeling condition, and the model establishment condition is evaluated by survival condition, graft-versus-host disease and rejection reaction observation, flow cytometry and histopathological section, so as to prove that the model is reliable and stable.

The present invention provides a novel use and methods comprising antibodies, or antigen-binding fragments thereof, which bind to a CCR7 receptor for use as a novel therapeutic agent in prevention and / or treatment of graft versus host disease (GVHD), preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. GVHD of the invention can be acute (aGVHD) and / or chronic (cGVHD), preferably acute. The antibodies and antigen-binding fragments are capable of selectively depleting ex vivo or in vitro immune cells expressing CCR7 and are capable in vivo of selectively killing immune cells expressing a CCR7 receptor and of impairing / blocking migration and of activation of said immune cells, which are involved in the development and evolution of GVHD. The use of said antibodies for depleting, killing and impairing / blocking migration and activation of immune cells expressing CCR7 cells is disclosed, thus providing an alternative therapy for preventing and treating GVHD in both acute and chronic types.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The present application belongs to the field of photochemical therapy, and particularly relates to a method for photochemical treatment of riboflavin based on multi-wavelength LED and application thereof in treatment of graft-versus-host disease. The present application selects different wavelength LED combinations as light sources to optimize the riboflavin photochemical method, controls the light intensity at 1000-25000 μW / cm², controls the irradiation time at 5-15 minutes, and controls the riboflavin concentration at 20-150 μM, thereby significantly improving the photochemical reaction effect. The method can efficiently induce PBMC apoptosis in a plasma environment, significantly reduces the levels of key pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-γ, and has no significant influence on platelets, hemoglobin and blood clotting function, thereby providing a safe and controllable new cell preparation method for GVHD treatment.

This invention relates to the selective removal of activated T cells using a monovalent antibody or its antigen-binding fragment, which includes heavy chain variable regions and light chain variable regions of an antibody that specifically binds to CD3. In one embodiment of the present invention, the monovalent anti-CD3 antibody or its antigen-binding fragment is useful as a T cell removal agent or T cell immunosuppressant because it can selectively remove only activated T cells without affecting non-activated T cells. In particular, this invention is useful for the prevention or treatment of T cell-mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, as well as for the prevention of graft-versus-host disease (GVHD) side effects in allogeneic CAR-T cell therapy.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

This invention relates to the field of cell engineering technology, and more particularly to a method for preparing immunomodulatory stem cells for treating graft-versus-host disease (GVHD). The invention provides a method for preparing immunomodulatory stem cells for treating GVHD, comprising the following steps: (1) washing human fat aspirate and digesting it with collagenase to obtain monocytes; (2) inoculating the monocytes obtained in step (1) into differentiation medium and culturing for 2–3 days, then continuing to culture the adherent cells for 18–22 days to obtain mesenchymal stem cells; (3) inoculating the mesenchymal stem cells obtained in step (2) into induction medium for induction culture, and after screening, obtaining immunomodulatory stem cells. The preparation method provided by this invention solves the technical problems of unstable sources, functional decline, and poor therapeutic effects of immunomodulatory stem cells in the prior art, providing a new, efficient, safe, and standardized solution for the treatment of GVHD.

A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.

The present disclosure provides antibodies that binds to human colony stimulating factor 1 receptor (CSF-1R) and methods of treating chronic graft-versus-host disease (cGVHD) with the antibodies.

Hyperimmunized egg product for the treatment or prevention of alcoholic liver disease and graft-versus-host disease. In one aspect, the present invention is directed to a method for preventing or treating alcoholic liver disease or graft-versus-host disease in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating alcoholic liver disease or graft-versus-host disease in the individual, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium.The present invention is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, cytolysin toxin isolated from Enterococcus faecalis, and Enterococcus faecium. Methods for preparing hyperimmunized eggs and egg products are also described.

This invention provides a peptide targeting graft-versus-host disease, its expression system, and a local in-situ regulatory system, belonging to the field of biomedical technology. This invention also provides the application of the peptide BigLEN in the preparation of macrophage pyroptosis inhibitors. BigLEN has a high affinity for the NLRP3 NACHT domain, and in vitro experiments have confirmed its effective inhibition of NLRP3-mediated pyroptosis in macrophages. This invention constructs a fusion protein and expression vector based on arabinose-induced expression, and an arabinose-inducible engineered EcN strain. Oral administration significantly improves survival rate, reduces intestinal pathological damage, decreases the infiltration of pro-inflammatory T cells, and promotes macrophage polarization towards an anti-inflammatory phenotype. This invention develops an orally administered engineered probiotic to precisely inhibit NLRP3-driven pyroptosis in intestinal macrophages.

The application discloses an antibody against human CD180 and application thereof. The antibody against human CD180 A24C9 and C12F11 provided by the application has strong affinity with human CD180 protein, and the Kd values are 0.4748 nM and 78.19 nM respectively; meanwhile, the antibody has strong binding specificity and can specifically recognize human CD180 positive acute myeloid leukemia (AML) cell lines (OCI-AML2, MV4-11, THP1) and human CD180 positive B cell lymphoma cell lines (Daudi, BJAB, Nalm6); and the antibody has no cross reaction with various human CD180 negative cell lines (K562, NB4, Kasumi1, TF1, NK92, Jurkat, SupT1 and MM1S). The antibody can be used for detecting expression of human CD180 protein, and can be used in immunotherapy alone or in combination with other methods, and has diagnostic and therapeutic values in tumors, autoimmune diseases, graft-versus-host diseases and inflammatory diseases.

The objectives are to provide an anti-PAD4 antibody with superior properties, or to provide an excellent method for preventing or treating rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, or graft-versus-host disease, etc. [Solution] The present invention provides an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 contains the amino acid sequence of SEQ ID NO: 1, HCDR2 contains the amino acid sequence of SEQ ID NO: 2, HCDR3 contains the amino acid sequence of SEQ ID NO: 3, LCDR1 contains the amino acid sequence of SEQ ID NO: 4, LCDR2 contains the amino acid sequence of SEQ ID NO: 5, and LCDR3 contains the amino acid sequence of SEQ ID NO: 6.

The present invention provides an antibody and an antigen-binding fragment (e.g., a human antibody) that specifically bind to human IL2 receptor gamma (IL2Rγ). A method for treating or preventing a disease mediated by IL2Rγ (e.g., graft-versus-host disease) using the antibody and the fragment is also provided along with a method for preparing the antibody and the fragment.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

The present invention relates to an isolated muropeptide of formula (I) GlcNAc-MurNAc-X1-Glu-mDAP-(Ala)Y1-(X2)Y2 as well as peptidoglycans (PG) comprising it and to a composition comprising at least one muropeptide and / or at least one PG and to the implementation of the muropeptide, peptidoglycan or composition in the prevention and / or treatment, in an individual in need thereof, of an immune disorder selected from the group consisting of an inflammatory disorder, graft-versus-host disease (GVHD) and graft rejection; or of an infection; or of a metabolic disorder or of a cancer.

This invention discloses a humanized Sirpα The construction methods of immunodeficient mice and their application in human immune reconstitution belong to the field of medical experimental model construction technology. Rag2 ‑ / ‑ IL2rg ‑ / ‑ Using animals with T, B, and NK cell immune dysfunction caused by mutations as the background strain, sgRNA and dsDNA were specifically designed, and their endogenous components were processed using CRISPR / Cas9 gene editing technology. Sirpα The entire genome was modified to be humanized, thus creating a humanized genome. Sirpα Immunodeficient mice. This method is simple to operate, highly reproducible, and constructs a fully humanized mouse. Sirpα Immunodeficient mice exhibit a higher immunodeficient phenotype and can achieve a higher rate of human T cell chimerism after transplantation with human peripheral blood mononuclear cells, while effectively reducing the risk of graft-host disease.

The present disclosure provides antibodies that binds to human colony stimulating factor 1 receptor (CSF-1R) and methods of treating chronic graft-versus-host disease (cGVHD) with the antibodies.